Healthcare Nov 16, 2021 10:33 PM (GMT+8) · EqualOcean
Yiouda health learned on the 16th that the CSRC announced that it agreed to register Baiji Shenzhou Co., Ltd. in the initial public offering of shares on the science and innovation board according to legal procedures. This means that if Baiji Shenzhou lands in the domestic A-share market, it will become the world's first biotechnology enterprise listed on Nasdaq, Hong Kong Stock Exchange and Shanghai Stock Exchange. It is reported that the IPO of Baiji Shenzhou science and Innovation Board plans to raise 20 billion yuan (after deducting the issuance expenses), which is the highest fund-raising amount of biotechnology enterprises since the opening of the science and innovation board. RMB 20 billion is mainly used for drug clinical trial R & D projects, R & D center construction projects, production base R & D and industrialization projects, marketing network construction projects and supplementary working capital, of which drug clinical trial R & D accounts for the largest proportion, with a planned investment of about RMB 13.25 billion.